WO2006136454A3 - Verwendung von inhibitorn der n-methyltransferasen in der therapie des parkinson-symdroms - Google Patents

Verwendung von inhibitorn der n-methyltransferasen in der therapie des parkinson-symdroms Download PDF

Info

Publication number
WO2006136454A3
WO2006136454A3 PCT/EP2006/006132 EP2006006132W WO2006136454A3 WO 2006136454 A3 WO2006136454 A3 WO 2006136454A3 EP 2006006132 W EP2006006132 W EP 2006006132W WO 2006136454 A3 WO2006136454 A3 WO 2006136454A3
Authority
WO
WIPO (PCT)
Prior art keywords
disease
parkinson
inhibitors
therapy
methyl transferases
Prior art date
Application number
PCT/EP2006/006132
Other languages
English (en)
French (fr)
Other versions
WO2006136454A2 (de
Inventor
Hans Uwe Wolf
Christoph Wilhelm
Original Assignee
Plt Patent & Licence Trading L
Hans Uwe Wolf
Christoph Wilhelm
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Plt Patent & Licence Trading L, Hans Uwe Wolf, Christoph Wilhelm filed Critical Plt Patent & Licence Trading L
Priority to US11/993,738 priority Critical patent/US20100143322A1/en
Priority to EP06754568A priority patent/EP1917006A2/de
Publication of WO2006136454A2 publication Critical patent/WO2006136454A2/de
Publication of WO2006136454A3 publication Critical patent/WO2006136454A3/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Die vorliegende Erfindung betrifft die Verwendung von Hemmstoffen verschiedener N-Methyltrans-f erasen in der Therapie des Parkinson-Syndroms, insbesondere des Idiopathischen Parkinson-Syndroms.
PCT/EP2006/006132 2005-06-24 2006-06-26 Verwendung von inhibitorn der n-methyltransferasen in der therapie des parkinson-symdroms WO2006136454A2 (de)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US11/993,738 US20100143322A1 (en) 2005-06-24 2006-06-26 Use of inhibitors of n-methyl transferases for the therapy of parkinson's disease
EP06754568A EP1917006A2 (de) 2005-06-24 2006-06-26 Verwendung von inhibitorn der n-methyltransferasen in der therapie des parkinson-symdroms

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102005029468A DE102005029468A1 (de) 2005-06-24 2005-06-24 Verwendung von Inhibitoren der N-Methyltransferasen in der Therapie des Parkinson-Syndroms
DE102005029468.5 2005-06-24

Publications (2)

Publication Number Publication Date
WO2006136454A2 WO2006136454A2 (de) 2006-12-28
WO2006136454A3 true WO2006136454A3 (de) 2007-11-01

Family

ID=37451171

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2006/006132 WO2006136454A2 (de) 2005-06-24 2006-06-26 Verwendung von inhibitorn der n-methyltransferasen in der therapie des parkinson-symdroms

Country Status (4)

Country Link
US (1) US20100143322A1 (de)
EP (1) EP1917006A2 (de)
DE (1) DE102005029468A1 (de)
WO (1) WO2006136454A2 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL381862A1 (pl) 2007-02-28 2008-09-01 Trigendo Spółka Z Ograniczoną Odpowiedzialnością Zastosowanie związków pirydyniowych i sposób leczenia
JP5497429B2 (ja) 2007-03-07 2014-05-21 武田薬品工業株式会社 ベンゾオキサゼピン誘導体およびその用途
US20120083464A1 (en) * 2009-06-11 2012-04-05 Proyecto De Biomedicina Cima, S.L. Neuroprotective properties of 5'-methylthioadenosine
CN109745313A (zh) 2010-08-11 2019-05-14 德雷克塞尔大学 治疗帕金森病中运动障碍的d3多巴胺受体激动剂
KR102266696B1 (ko) 2013-10-28 2021-06-21 드렉셀유니버시티 주의력 및 인지 장애, 및 신경 퇴행성 장애와 관련된 치매 치료용 신규 치료제
WO2022160056A1 (en) * 2021-01-29 2022-08-04 Algernon Pharmaceuticals Inc. Dmt salts and their use to treat brain injury

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001030346A1 (en) * 1999-10-22 2001-05-03 The Victoria University Of Manchester Treatment of dyskinesia
WO2003035675A1 (en) * 2001-10-26 2003-05-01 Liesi Paeivi Biologically active peptides and their use for repairing injured nerves
US20030119750A1 (en) * 2001-06-27 2003-06-26 Hans-Ulrich Demuth Use of dipeptidyl peptidase IV inhibitors
US20040005304A1 (en) * 2002-07-08 2004-01-08 Mak Wood, Inc. Novel compositions and methods for treating neurological disorders and associated gastrointestinal conditions
US20040087487A1 (en) * 1998-06-15 2004-05-06 Gluckman Peter D. Regulation of tyrosine hydroxylase by gpe
WO2004069175A2 (en) * 2003-02-02 2004-08-19 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services METHODS AND COMPOSITIONS FOR THE TREATMENT OF PARKINSON’S DISEASE AND OTHER α-SYNUCLEINOPATHIES
US6815425B1 (en) * 1999-10-22 2004-11-09 The United States Of America As Represented By The Secretary Of The Army Pharmaceutical composition containing pGLU-GLU-PRO-NH2 and method for treating diseases and injuries to the brain, spinal cord and retina using same

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4078997A (en) * 1996-08-22 1998-03-06 New York University Cholinesterase inhibitors for treatment of parkinson's disease

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040087487A1 (en) * 1998-06-15 2004-05-06 Gluckman Peter D. Regulation of tyrosine hydroxylase by gpe
WO2001030346A1 (en) * 1999-10-22 2001-05-03 The Victoria University Of Manchester Treatment of dyskinesia
US6815425B1 (en) * 1999-10-22 2004-11-09 The United States Of America As Represented By The Secretary Of The Army Pharmaceutical composition containing pGLU-GLU-PRO-NH2 and method for treating diseases and injuries to the brain, spinal cord and retina using same
US20030119750A1 (en) * 2001-06-27 2003-06-26 Hans-Ulrich Demuth Use of dipeptidyl peptidase IV inhibitors
WO2003035675A1 (en) * 2001-10-26 2003-05-01 Liesi Paeivi Biologically active peptides and their use for repairing injured nerves
US20040005304A1 (en) * 2002-07-08 2004-01-08 Mak Wood, Inc. Novel compositions and methods for treating neurological disorders and associated gastrointestinal conditions
WO2004069175A2 (en) * 2003-02-02 2004-08-19 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services METHODS AND COMPOSITIONS FOR THE TREATMENT OF PARKINSON’S DISEASE AND OTHER α-SYNUCLEINOPATHIES

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
See also references of EP1917006A2 *
STORCH ALEXANDER ET AL: "Selective dopaminergic neurotoxicity of isoquinoline derivatives related to Parkinson's disease: Studies using heterologous expression systems of the dopamine transporter", BIOCHEMICAL PHARMACOLOGY, vol. 63, no. 5, 1 March 2002 (2002-03-01), pages 909 - 920, XP002434492, ISSN: 0006-2952 *
WILHELM C ET AL: "Further purification and isolation of an N-methyltransferase inhibitor with possible significance in the pathomechanism of the idiopathic Parkinson syndrome.", NAUNYN-SCHMIEDEBERG'S ARCHIVES OF PHARMACOLOGY, vol. 367, no. Supplement 1, March 2003 (2003-03-01), & 44TH SPRING MEETING OF THE DEUTSCHE GESELLSCHAFT FUER EXPERIMENTELLE UND KLINISCHE PHARMAKOLOGIE UND; MAINZ, GERMANY; MARCH 17-20, 2003, pages R133, XP002434494, ISSN: 0028-1298 *
WILHELM C ET AL: "Purification and characterisation of an N-Methyltransferase inhibitor from rabbit liver", NAUNYN-SCHMIEDEBERG'S ARCHIVES OF PHARMACOLOGY, vol. 363, no. 4 Supplement, 2001, & 42ND SPRING MEETING OF THE GERMAN SOCIETY FOR EXPERIMENTAL AND CLLINICAL PHARMACOLOGY AND TOXICOLOGY; MAINZ, GERMANY; MARCH 13-15, 2001, pages R142, XP009083992, ISSN: 0028-1298 *
WILHELM CHR ET AL: "Further purification and characterization of an N-methyl-transferase inhibitor with possible significance in the pathomechanism of the Idiopathic Parkinson syndrome", NAUNYN-SCHMIEDEBERG'S ARCHIVES OF PHARMACOLOGY, vol. 365, no. Supplement 1, March 2002 (2002-03-01), & 43RD SPRING MEETING OF THE GERMAN SOCIETY FOR EXPERIMENTAL AND CLINICAL PHARMACOLOGY AND TOXICOLOGY; MAINZ, GERMANY; MARCH 12-14, 2002, pages R130, XP002434493, ISSN: 0028-1298 *

Also Published As

Publication number Publication date
WO2006136454A2 (de) 2006-12-28
EP1917006A2 (de) 2008-05-07
US20100143322A1 (en) 2010-06-10
DE102005029468A1 (de) 2006-12-28

Similar Documents

Publication Publication Date Title
WO2008076392A3 (en) Compounds useful as protein kinase inhibitors
WO2007095188A3 (en) Dihydrodiazepines useful as inhibitors of protein kinases
WO2008137619A3 (en) Thiazoles and pyrazoles useful as kinase inhibitors
WO2008147626A3 (en) Thiazoles and pyrazoles useful as kinase inhibitors
MX2009008253A (es) Derivados de 2-aminopiridina utiles como inhibidores de cinasa.
WO2007127505A3 (en) Use of sulfonamide derivatives in the treatment of disorders of the metabolism and the nervous system
WO2005103050A3 (en) Azaindoles useful as inhibitors of rock and other protein kinases
WO2008115973A3 (en) Aminopyrimidines useful as kinase inhibitors
WO2007056163A3 (en) Aminopyrimidines useful as kinase inhibitors
ZA200708361B (en) Compositions and methods for increasing metabolism, thermogenesis and/or muscular definition
WO2005105780A3 (en) Compositions useful as inhibitors of rock and other protein kinases
WO2007146965A3 (en) Compounds for the treatment of periodontal disease
WO2008112651A3 (en) Aminopyrimidines useful as inhibitors of protein kinases
HUE059861T2 (hu) N-Szubsztituált 2,5-dioxo-azolin vegyületek a rák kezelésében való felhasználásra
AU2006224295A8 (en) N- (N-sulfonylaminomethyl) cyclopropanecarboxamide derivatives useful for the treatment of pain
WO2007139816A3 (en) Thiophene-carboxamides useful as inhibitors of protein kinases
WO2008137622A3 (en) Aminopyrimidines useful as kinase inhibitors
WO2007137071A3 (en) Compositions of r(+) and s(-) pramipexole and methods of using the same
WO2007087283A3 (en) Thiophene-carboxamides useful as inhibitors of protein kinases
IL186130A0 (en) 3,4,5-substituted piperidines as renin inhibitors
WO2007120760A3 (en) Thiophene-carboxamides useful as inhibitors of protein kinases
EP1855679A4 (de) Aminomethyl-beta-sekretase-hemmer zur behandlung von alzheimer
WO2008003943A3 (en) Inhibition of alpha-synuclein aggregation
WO2006116221A3 (en) Therapeutic combinations for the treatment or prevention of psychotic disorders
WO2007092496A3 (en) 7,9-dihydro-purin-8-one and related analogs as hsp90-inhibitors

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

WWE Wipo information: entry into national phase

Ref document number: 2006754568

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2006754568

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 11993738

Country of ref document: US